Tags

Type your tag names separated by a space and hit enter

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021.
MMWR Morb Mortal Wkly Rep. 2021 May 21; 70(20):749-752.MM

Abstract

The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 intramuscular doses (30 μg, 0.3 mL each) administered 3 weeks apart. On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for use of the Pfizer-BioNTech COVID-19 vaccine (Pfizer, Inc; Philadelphia, Pennsylvania) in persons aged ≥16 years (1); on December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the vaccine in the same age group (2). As of May 12, 2021, approximately 141.6 million doses of the Pfizer-BioNTech COVID-19 vaccine had been administered to persons aged ≥16 years.* On May 10, 2021, FDA expanded the EUA for the Pfizer-BioNTech COVID-19 vaccine to include adolescents aged 12-15 years (1). On May 12, 2021, ACIP issued an interim recommendation† for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP used the Evidence to Recommendation (EtR) Framework,§ using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.¶ The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥12 years under an EUA is interim and will be updated as additional information becomes available.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34014913

Citation

Wallace, Megan, et al. "The Advisory Committee On Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021." MMWR. Morbidity and Mortality Weekly Report, vol. 70, no. 20, 2021, pp. 749-752.
Wallace M, Woodworth KR, Gargano JW, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021. MMWR Morb Mortal Wkly Rep. 2021;70(20):749-752.
Wallace, M., Woodworth, K. R., Gargano, J. W., Scobie, H. M., Blain, A. E., Moulia, D., Chamberland, M., Reisman, N., Hadler, S. C., MacNeil, J. R., Campos-Outcalt, D., Morgan, R. L., Daley, M. F., Romero, J. R., Talbot, H. K., Lee, G. M., Bell, B. P., & Oliver, S. E. (2021). The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021. MMWR. Morbidity and Mortality Weekly Report, 70(20), 749-752. https://doi.org/10.15585/mmwr.mm7020e1
Wallace M, et al. The Advisory Committee On Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021. MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):749-752. PubMed PMID: 34014913.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021. AU - Wallace,Megan, AU - Woodworth,Kate R, AU - Gargano,Julia W, AU - Scobie,Heather M, AU - Blain,Amy E, AU - Moulia,Danielle, AU - Chamberland,Mary, AU - Reisman,Nicole, AU - Hadler,Stephen C, AU - MacNeil,Jessica R, AU - Campos-Outcalt,Doug, AU - Morgan,Rebecca L, AU - Daley,Matthew F, AU - Romero,José R, AU - Talbot,H Keipp, AU - Lee,Grace M, AU - Bell,Beth P, AU - Oliver,Sara E, Y1 - 2021/05/21/ PY - 2021/5/20/entrez PY - 2021/5/21/pubmed PY - 2021/5/22/medline SP - 749 EP - 752 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 70 IS - 20 N2 - The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 intramuscular doses (30 μg, 0.3 mL each) administered 3 weeks apart. On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for use of the Pfizer-BioNTech COVID-19 vaccine (Pfizer, Inc; Philadelphia, Pennsylvania) in persons aged ≥16 years (1); on December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the vaccine in the same age group (2). As of May 12, 2021, approximately 141.6 million doses of the Pfizer-BioNTech COVID-19 vaccine had been administered to persons aged ≥16 years.* On May 10, 2021, FDA expanded the EUA for the Pfizer-BioNTech COVID-19 vaccine to include adolescents aged 12-15 years (1). On May 12, 2021, ACIP issued an interim recommendation† for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP used the Evidence to Recommendation (EtR) Framework,§ using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.¶ The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥12 years under an EUA is interim and will be updated as additional information becomes available. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/34014913/The_Advisory_Committee_on_Immunization_Practices'_Interim_Recommendation_for_Use_of_Pfizer_BioNTech_COVID_19_Vaccine_in_Adolescents_Aged_12_15_Years___United_States_May_2021_ L2 - https://doi.org/10.15585/mmwr.mm7020e1 DB - PRIME DP - Unbound Medicine ER -